TimeZone (America/Los Angeles)
Engineering T Cells to Conquer Cancer
Monday, June 10, 2013 11:00:00 AM PDT - 11:45:00 AM PDT
Carl H. June, M.D., a specialist in T cell biology and lymphocyte activation at the Perelman School of Medicine, University of Pennsylvania, will discuss his groundbreaking work that has led to remarkable remissions of advanced cancer. He will focus on recent and ongoing successes in developing treatments with T cells that have been genetically engineered to target cancer. Called chimeric antigen receptor T cells (CAR T cells), these modified immune cells have proven effective at eliminating cancer in some patients, and offer great hope for this emerging strategy in cancer immunotherapy.


Carl H. June, M.D., Perelman School of Medicine, UPenn
Carl H. June, M.D., is director of Translational Research at the Abramson Cancer Center at the University of Pennsylvania, is an investigator of the Abramson Family Cancer Research Institute, and is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania. 

If you've never used Adobe Connect, get a quick overview: http://www.adobe.com/products/adobeconnect.html
Adobe, the Adobe logo, Acrobat and Adobe Connect are either registered trademarks or trademarks
of Adobe Systems Incorporated in the United States and/or other countries.